204 related articles for article (PubMed ID: 38325562)
1. Unlocking the Mitochondria for Nanomedicine-based Treatments: Overcoming Biological Barriers, Improving Designs, and Selecting Verification Techniques.
Pegoraro C; Domingo-Ortí I; Conejos-Sánchez I; Vicent MJ
Adv Drug Deliv Rev; 2024 Apr; 207():115195. PubMed ID: 38325562
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicines for Subcellular Targeting: The Mitochondrial Perspective.
Oladimeji O; Akinyelu J; Singh M
Curr Med Chem; 2020; 27(33):5480-5509. PubMed ID: 31763965
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicines for back of the eye drug delivery, gene delivery, and imaging.
Kompella UB; Amrite AC; Pacha Ravi R; Durazo SA
Prog Retin Eye Res; 2013 Sep; 36():172-98. PubMed ID: 23603534
[TBL] [Abstract][Full Text] [Related]
4. Physiological determinants and plausible '6R' roadmap for clinical success of nanomedicines.
Shahiwala A
Nanomedicine (Lond); 2023 Aug; 18(18):1207-1222. PubMed ID: 37650539
[TBL] [Abstract][Full Text] [Related]
5. Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges.
Lin G; Zhou J; Cheng H; Liu G
Small; 2023 Jul; 19(28):e2207973. PubMed ID: 36971279
[TBL] [Abstract][Full Text] [Related]
6. Insight into nanoparticle cellular uptake and intracellular targeting.
Yameen B; Choi WI; Vilos C; Swami A; Shi J; Farokhzad OC
J Control Release; 2014 Sep; 190():485-99. PubMed ID: 24984011
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary delivery nanomedicines towards circumventing physiological barriers: Strategies and characterization approaches.
Wang W; Huang Z; Huang Y; Zhang X; Huang J; Cui Y; Yue X; Ma C; Fu F; Wang W; Wu C; Pan X
Adv Drug Deliv Rev; 2022 Jun; 185():114309. PubMed ID: 35469997
[TBL] [Abstract][Full Text] [Related]
8. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity.
Ryu JH; Yoon HY; Sun IC; Kwon IC; Kim K
Adv Mater; 2020 Dec; 32(51):e2002197. PubMed ID: 33051905
[TBL] [Abstract][Full Text] [Related]
10. Targeted nanomedicine in cisplatin-based cancer therapeutics.
Han Y; Wen P; Li J; Kataoka K
J Control Release; 2022 May; 345():709-720. PubMed ID: 35367476
[TBL] [Abstract][Full Text] [Related]
11. Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery.
Waheed S; Li Z; Zhang F; Chiarini A; Armato U; Wu J
J Nanobiotechnology; 2022 Aug; 20(1):395. PubMed ID: 36045386
[TBL] [Abstract][Full Text] [Related]
12. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
13. Obstacles and opportunities in a forward vision for cancer nanomedicine.
de Lázaro I; Mooney DJ
Nat Mater; 2021 Nov; 20(11):1469-1479. PubMed ID: 34226688
[TBL] [Abstract][Full Text] [Related]
14. Stimuli-Responsive Programmed Specific Targeting in Nanomedicine.
Wang S; Huang P; Chen X
ACS Nano; 2016 Mar; 10(3):2991-4. PubMed ID: 26881288
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance.
Zhou L; Wang H; Li Y
Theranostics; 2018; 8(4):1059-1074. PubMed ID: 29463999
[TBL] [Abstract][Full Text] [Related]
16. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
Qin SY; Zhang AQ; Zhang XZ
Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
[TBL] [Abstract][Full Text] [Related]
17. The spatiotemporal journey of nanomedicines in solid tumors on their therapeutic efficacy.
Qin M; Xia H; Xu W; Chen B; Wang Y
Adv Drug Deliv Rev; 2023 Dec; 203():115137. PubMed ID: 37949414
[TBL] [Abstract][Full Text] [Related]
18. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
19. Deepened cellular/subcellular interface penetration and enhanced antitumor efficacy of cyclic peptidic ligand-decorated accelerating active targeted nanomedicines.
Shi NQ; Li Y; Zhang Y; Li ZQ; Qi XR
Int J Nanomedicine; 2018; 13():5537-5559. PubMed ID: 30271146
[TBL] [Abstract][Full Text] [Related]
20. Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines.
Battistella C; Klok HA
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28444959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
